Status:
COMPLETED
NovellusDx Functional Profiling of Oncogenic Mutations in Lung Cancer Patients
Lead Sponsor:
Fore Biotherapeutics
Collaborating Sponsors:
Rabin Medical Center
Conditions:
Lung Cancer
Eligibility:
All Genders
18-85 years
Brief Summary
NovellusDx technology identifies tumor-specific driver mutations, but unlike sequencing-based tests, NovellusDx has a functional assay that detects dis-regulated translocation of mutated signaling pro...
Eligibility Criteria
Inclusion
- Patients that are suspected to have lung cancer and are eligible for biopsy, surgical intervention or pleural fluid suction
Exclusion
- Patients without lung cancer
Key Trial Info
Start Date :
October 1 2014
Trial Type :
OBSERVATIONAL
Allocation :
ACTUAL
End Date :
October 1 2016
Estimated Enrollment :
20 Patients enrolled
Trial Details
Trial ID
NCT02274025
Start Date
October 1 2014
End Date
October 1 2016
Last Update
March 29 2018
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
Rabin Medical Center, Beilinson
Petah Tikva, Israel